CR20210077A - Nuevos compuestos heterocíclicos como inhibidores de la monoacilglicerol lipasa - Google Patents
Nuevos compuestos heterocíclicos como inhibidores de la monoacilglicerol lipasaInfo
- Publication number
- CR20210077A CR20210077A CR20210077A CR20210077A CR20210077A CR 20210077 A CR20210077 A CR 20210077A CR 20210077 A CR20210077 A CR 20210077A CR 20210077 A CR20210077 A CR 20210077A CR 20210077 A CR20210077 A CR 20210077A
- Authority
- CR
- Costa Rica
- Prior art keywords
- heterocyclic compounds
- new heterocyclic
- lipase inhibitors
- monoacylglycerol lipase
- compounds
- Prior art date
Links
- 150000002391 heterocyclic compounds Chemical class 0.000 title abstract 2
- 229940127470 Lipase Inhibitors Drugs 0.000 title 1
- 102000005398 Monoacylglycerol Lipase Human genes 0.000 title 1
- 108020002334 Monoacylglycerol lipase Proteins 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- 238000000034 method Methods 0.000 abstract 2
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Plural Heterocyclic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
<p>La invención proporciona nuevos compuestos heterocíclicos que presentan la fórmula general (I) en donde A, L, X, m, n, R1 y R2 son como se describe en la presente, composiciones que incluyen los compuestos, procesos de fabricación de los compuestos y métodos de utilización de los compuestos.</p>
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18188681 | 2018-08-13 | ||
| PCT/EP2019/071520 WO2020035424A1 (en) | 2018-08-13 | 2019-08-12 | New heterocyclic compounds as monoacylglycerol lipase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CR20210077A true CR20210077A (es) | 2021-03-11 |
Family
ID=63244467
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CR20210077A CR20210077A (es) | 2018-08-13 | 2019-08-12 | Nuevos compuestos heterocíclicos como inhibidores de la monoacilglicerol lipasa |
Country Status (33)
| Country | Link |
|---|---|
| US (4) | US20200308190A1 (es) |
| EP (2) | EP4474017A3 (es) |
| JP (2) | JP7637049B2 (es) |
| KR (1) | KR102879259B1 (es) |
| CN (1) | CN112867720A (es) |
| AR (1) | AR116666A1 (es) |
| AU (1) | AU2019322538B2 (es) |
| BR (1) | BR112021002298A2 (es) |
| CA (1) | CA3104928A1 (es) |
| CL (1) | CL2021000362A1 (es) |
| CO (1) | CO2021002382A2 (es) |
| CR (1) | CR20210077A (es) |
| DK (1) | DK3837263T3 (es) |
| ES (1) | ES2986417T3 (es) |
| FI (1) | FI3837263T3 (es) |
| HR (1) | HRP20241201T1 (es) |
| HU (1) | HUE067912T2 (es) |
| IL (1) | IL279173B2 (es) |
| LT (1) | LT3837263T (es) |
| MA (1) | MA53219B1 (es) |
| MX (1) | MX2021001433A (es) |
| MY (1) | MY210507A (es) |
| PE (1) | PE20211089A1 (es) |
| PH (1) | PH12021500013A1 (es) |
| PL (1) | PL3837263T3 (es) |
| PT (1) | PT3837263T (es) |
| RS (1) | RS65912B1 (es) |
| RU (1) | RU2769507C1 (es) |
| SG (1) | SG11202013064WA (es) |
| SI (1) | SI3837263T1 (es) |
| TW (1) | TWI812770B (es) |
| UA (1) | UA127629C2 (es) |
| WO (1) | WO2020035424A1 (es) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR114136A1 (es) | 2017-10-10 | 2020-07-29 | Hoffmann La Roche | Compuestos heterocíclicos |
| WO2019105915A1 (en) | 2017-11-28 | 2019-06-06 | F. Hoffmann-La Roche Ag | New heterocyclic compounds |
| WO2019134985A1 (en) | 2018-01-08 | 2019-07-11 | F. Hoffmann-La Roche Ag | Octahydropyrido[1,2-alpha]pyrazines as magl inhibitors |
| TWI877770B (zh) | 2018-02-27 | 2025-03-21 | 美商英塞特公司 | 作為a2a / a2b抑制劑之咪唑并嘧啶及三唑并嘧啶 |
| EP3810610A1 (en) | 2018-05-18 | 2021-04-28 | Incyte Corporation | Fused pyrimidine derivatives as a2a / a2b inhibitors |
| WO2020010197A1 (en) | 2018-07-05 | 2020-01-09 | Incyte Corporation | Fused pyrazine derivatives as a2a / a2b inhibitors |
| PE20211089A1 (es) * | 2018-08-13 | 2021-06-14 | Hoffmann La Roche | Nuevos compuestos heterociclicos como inhibidores de la monoacilglicerol lipasa |
| WO2020104494A1 (en) | 2018-11-22 | 2020-05-28 | F. Hoffmann-La Roche Ag | New heterocyclic compounds |
| TWI829857B (zh) | 2019-01-29 | 2024-01-21 | 美商英塞特公司 | 作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶 |
| KR20220058553A (ko) * | 2019-09-05 | 2022-05-09 | 루난 파마슈티컬 그룹 코퍼레이션 | Magl 억제제 및 이의 제조 방법, 용도 |
| US20210094971A1 (en) * | 2019-09-09 | 2021-04-01 | Hoffmann-La Roche Inc. | Heterocyclic compounds |
| CN114269755A (zh) * | 2019-09-12 | 2022-04-01 | 豪夫迈·罗氏有限公司 | 作为magl抑制剂的4,4a,5,7,8,8a-六吡啶并[4,3-b][1,4]噁嗪-3-酮化合物 |
| PH12022550433A1 (en) * | 2019-09-23 | 2024-01-29 | Hoffmann La Roche | Heterocyclic compounds |
| CR20220117A (es) * | 2019-09-24 | 2022-04-20 | F Horrmann La Roche Ag | Compuestos heterocíclicos |
| WO2021058445A1 (en) * | 2019-09-24 | 2021-04-01 | F. Hoffmann-La Roche Ag | New heterocyclic monoacylglycerol lipase (magl) inhibitors |
| BR112022006507A2 (pt) | 2019-10-07 | 2022-06-28 | De Shaw Res Llc | Compostos heterocíclicos de arilmetileno como bloqueadores de canais de agitador de potássio kv1.3 |
| WO2021191391A1 (en) * | 2020-03-26 | 2021-09-30 | Janssen Pharmaceutica Nv | Aminocyclobutanes as monoacylglycerol lipase modulators |
| CA3190277A1 (en) | 2020-09-03 | 2022-03-10 | Joerg Benz | Heterocyclic compounds |
| CA3242372A1 (en) | 2021-12-29 | 2023-07-06 | Psy Therapeutics, Inc. | Inhibiting monoacylglycerol lipase (magl) |
| IL318647A (en) | 2022-08-05 | 2025-03-01 | Kumquat Biosciences Inc | Heterocyclic compounds and their uses |
| EP4665718A1 (en) | 2023-02-13 | 2025-12-24 | Apogee Pharmaceuticals, Inc. | Small molecules as monoacylglycerol lipase (magl) inhibitors, compositions and use thereof |
Family Cites Families (64)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5214038A (en) | 1991-04-15 | 1993-05-25 | Hoechst-Roussel Pharmaceuticals Inc. | 1-(pyrido[3,4-b]-1,4-oxazinyl-4-yl)-1H-indoles and intermediates for the preparation thereof |
| US7544678B2 (en) | 2002-11-05 | 2009-06-09 | The Trustees Of Columbia University In The City Of New York | Anti-arrythmic and heart failure drugs that target the leak in the ryanodine receptor (RyR2) |
| US7160888B2 (en) | 2003-08-22 | 2007-01-09 | Warner Lambert Company Llc | [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia |
| US7579495B2 (en) | 2003-12-19 | 2009-08-25 | Momentive Performance Materials Inc. | Active-releasing cyclic siloxanes |
| JP5023054B2 (ja) | 2005-03-31 | 2012-09-12 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | 抗バクテリア剤としての二環式ピラゾール化合物 |
| ATE450525T1 (de) | 2005-06-20 | 2009-12-15 | Schering Corp | Kohlenstoffgebundene substituierte piperidine und derivate daraus als histamin-h3-antagonisten |
| JP5116687B2 (ja) | 2005-11-02 | 2013-01-09 | バイエル・ファルマ・アクチェンゲゼルシャフト | がんおよび他の過剰増殖性疾患の処置のためのピロロ［２，１−ｆ］［１，２，４］トリアジン−４−イルアミンＩＧＦ−１Ｒキナーゼ阻害剤 |
| EP1984351A1 (en) | 2006-02-17 | 2008-10-29 | Memory Pharmaceuticals Corporation | Compounds having 5-ht6 receptor affinity |
| US7872028B2 (en) | 2006-04-05 | 2011-01-18 | Vitae Pharmaceuticals, Inc. | Diaminopropanol renin inhibitors |
| KR102107954B1 (ko) | 2007-03-12 | 2020-05-07 | 인트라-셀룰라 써래피스, 인코퍼레이티드. | 치환된 헤테로환 융합 감마-카르볼린 합성 |
| FR2915197B1 (fr) * | 2007-04-18 | 2009-06-12 | Sanofi Aventis Sa | Derives de triazolopyridine-carboxamides, leur preparation et leur application therapeutique. |
| TW200938542A (en) | 2008-02-01 | 2009-09-16 | Irm Llc | Compounds and compositions as kinase inhibitors |
| JP5314123B2 (ja) | 2008-03-31 | 2013-10-16 | シー アンド シー リサーチ ラボラトリーズ | 複素環誘導体 |
| BRPI0919648A2 (pt) | 2008-10-29 | 2015-12-08 | Hoffmann La Roche | novos derivados de fenil amida ou piridil amida e seu uso como agonistas de gpbar1 |
| JP5658756B2 (ja) | 2009-09-10 | 2015-01-28 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | Ｊａｋの阻害剤 |
| WO2011059118A1 (ko) | 2009-11-10 | 2011-05-19 | Kim Hyun Jeen | 후각인지능력 검사 시스템 |
| WO2011058766A1 (en) * | 2009-11-16 | 2011-05-19 | Raqualia Pharma Inc. | Aryl carboxamide derivatives as ttx-s blockers |
| US8420661B2 (en) | 2010-04-13 | 2013-04-16 | Hoffmann-La Roche Inc. | Arylethynyl derivatives |
| CN103781763B (zh) | 2011-05-16 | 2017-03-22 | 生态学有限公司 | 作为钾通道阻断剂的胺衍生物 |
| US20140288323A1 (en) | 2011-10-19 | 2014-09-25 | The Trustees Of Columbia University In The City Of New York | Cyclopropenimine catalyst compositions and processes |
| TW201326180A (zh) | 2011-11-30 | 2013-07-01 | Actelion Pharmaceuticals Ltd | ３，７－二取代八氫－２Ｈ－吡啶并［４，３－ｅ］［１，３］□嗪－２－酮抗生素 |
| JO3398B1 (ar) | 2011-12-22 | 2019-10-20 | Novartis Ag | مشتقات 2،3- ثانى هيدرو- بنزو[1,4] أوكسازين والمركبات المتعلقة بها كمثبطات كيناز فسفواينوسيتيد-3 (pi3k) لمعالجة على سبيل المثال التهاب المفاصل الروماتيدي |
| US9487495B2 (en) | 2012-01-06 | 2016-11-08 | The Scripts Research Institute | Carbamate compounds and of making and using same |
| GB201209587D0 (en) | 2012-05-30 | 2012-07-11 | Takeda Pharmaceutical | Therapeutic compounds |
| TW201422625A (zh) | 2012-11-26 | 2014-06-16 | Novartis Ag | 二氫－吡啶并－□衍生物之固體形式 |
| TWI644671B (zh) | 2013-03-14 | 2018-12-21 | 比利時商健生藥品公司 | Ｐ２ｘ７調節劑 |
| KR20150143720A (ko) | 2013-04-16 | 2015-12-23 | 액테리온 파마슈티칼 리미티드 | 항균성 이방향족 유도체 |
| WO2016109501A1 (en) | 2014-12-30 | 2016-07-07 | Karos Pharmaceuticals, Inc. | Amide compounds as tryptophan hydroxylase inhibitors |
| JP6653319B2 (ja) | 2015-03-30 | 2020-02-26 | 武田薬品工業株式会社 | 複素環化合物 |
| CA2979302A1 (en) | 2015-05-13 | 2016-11-17 | Selvita S.A. | Substituted quinoxaline derivatives |
| KR20180005250A (ko) | 2015-05-21 | 2018-01-15 | 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 | Pad4 억제제로서의 벤조이미다졸 유도체 |
| WO2016205590A1 (en) | 2015-06-18 | 2016-12-22 | Cephalon, Inc. | Substituted 4-benzyl and 4-benzoyl piperidine derivatives |
| UA121775C2 (uk) | 2015-07-31 | 2020-07-27 | Пфайзер Інк. | 1,1,1-трифтор-3-гідроксипропан-2-ілкарбаматні похідні та 1,1,1-трифтор-4-гідроксибутан-2-ілкарбаматні похідні як інгібітори magl |
| WO2017087858A1 (en) | 2015-11-20 | 2017-05-26 | Abide Therapeutics, Inc. | Pyrazole compounds and methods of making and using same |
| WO2017087863A1 (en) | 2015-11-20 | 2017-05-26 | Abide Therapeutics, Inc. | Pyrazole compounds and methods of making and using same |
| EA036637B1 (ru) | 2016-03-31 | 2020-12-02 | Такеда Фармасьютикал Компани Лимитед | Гетероциклические спиросоединения, ингибирующие моноацилглицерин-липазу |
| WO2017170830A1 (ja) * | 2016-03-31 | 2017-10-05 | 武田薬品工業株式会社 | 複素環化合物 |
| EP3478678A1 (en) | 2016-06-30 | 2019-05-08 | Basilea Pharmaceutica International AG | Mitochondrial inhibitors for the treatment of proliferation disorders |
| DK3541807T3 (da) | 2016-11-16 | 2021-12-06 | H Lundbeck As | Krystallinsk form af en magl-inhibitor |
| JOP20190107A1 (ar) | 2016-11-16 | 2019-05-09 | Lundbeck La Jolla Research Center Inc | مثبطات أحادي أسيل جليسرول ليباز (magl) |
| AU2018285131B2 (en) | 2017-06-12 | 2021-11-11 | Boehringer Ingelheim International Gmbh | Heteroaromatic compounds as Vanin inhibitors |
| MX2020007318A (es) | 2017-09-29 | 2020-08-24 | Takeda Pharmaceuticals Co | Compuesto heterociclico. |
| AR114136A1 (es) | 2017-10-10 | 2020-07-29 | Hoffmann La Roche | Compuestos heterocíclicos |
| WO2019105915A1 (en) | 2017-11-28 | 2019-06-06 | F. Hoffmann-La Roche Ag | New heterocyclic compounds |
| TW201930300A (zh) | 2017-12-15 | 2019-08-01 | 瑞士商赫孚孟拉羅股份公司 | 新雜環化合物 |
| WO2019134985A1 (en) | 2018-01-08 | 2019-07-11 | F. Hoffmann-La Roche Ag | Octahydropyrido[1,2-alpha]pyrazines as magl inhibitors |
| ES2942319T3 (es) * | 2018-03-22 | 2023-05-31 | Hoffmann La Roche | Inhibidores de oxacina monoacilglicerol lipasa (MAGL) |
| PE20211089A1 (es) | 2018-08-13 | 2021-06-14 | Hoffmann La Roche | Nuevos compuestos heterociclicos como inhibidores de la monoacilglicerol lipasa |
| AU2019322161A1 (en) | 2018-08-13 | 2020-11-12 | F. Hoffmann-La Roche Ag | New heterocyclic compounds as monoacylglycerol lipase inhibitors |
| MA54555A (fr) | 2018-11-22 | 2021-09-29 | Qilu Regor Therapeutics Inc | Agonistes de glp-1r et leurs utilisations |
| WO2020104494A1 (en) | 2018-11-22 | 2020-05-28 | F. Hoffmann-La Roche Ag | New heterocyclic compounds |
| EP3953360B1 (en) | 2019-04-09 | 2024-02-28 | F. Hoffmann-La Roche AG | Heterocyclic compounds as inhibitors of monoacylglycerol lipase (magl) |
| MX2022000083A (es) | 2019-07-03 | 2022-02-03 | Hoffmann La Roche | Inhibidores de monoacilglicerol lipasa (magl) heterociclicos. |
| CN114096545A (zh) | 2019-07-09 | 2022-02-25 | 豪夫迈·罗氏有限公司 | 新杂环化合物 |
| US20210094971A1 (en) | 2019-09-09 | 2021-04-01 | Hoffmann-La Roche Inc. | Heterocyclic compounds |
| WO2021048241A1 (en) | 2019-09-12 | 2021-03-18 | F. Hoffmann-La Roche Ag | Radiolabeled compounds |
| CN114269755A (zh) | 2019-09-12 | 2022-04-01 | 豪夫迈·罗氏有限公司 | 作为magl抑制剂的4,4a,5,7,8,8a-六吡啶并[4,3-b][1,4]噁嗪-3-酮化合物 |
| PH12022550433A1 (en) | 2019-09-23 | 2024-01-29 | Hoffmann La Roche | Heterocyclic compounds |
| WO2021058443A1 (en) | 2019-09-24 | 2021-04-01 | F. Hoffmann-La Roche Ag | Fluorescent probes for monoacylglycerol lipase (magl) |
| WO2021058445A1 (en) | 2019-09-24 | 2021-04-01 | F. Hoffmann-La Roche Ag | New heterocyclic monoacylglycerol lipase (magl) inhibitors |
| CR20220117A (es) | 2019-09-24 | 2022-04-20 | F Horrmann La Roche Ag | Compuestos heterocíclicos |
| JP7785755B2 (ja) | 2020-08-26 | 2025-12-15 | エフ． ホフマン－ラ ロシュ アーゲー | Ｍａｇｌ阻害剤として有用な複素環化合物 |
| CA3190277A1 (en) | 2020-09-03 | 2022-03-10 | Joerg Benz | Heterocyclic compounds |
| CN117295726A (zh) | 2021-04-23 | 2023-12-26 | 豪夫迈·罗氏有限公司 | 杂环化合物 |
-
2019
- 2019-08-12 PE PE2021000135A patent/PE20211089A1/es unknown
- 2019-08-12 JP JP2021507457A patent/JP7637049B2/ja active Active
- 2019-08-12 HU HUE19755855A patent/HUE067912T2/hu unknown
- 2019-08-12 DK DK19755855.4T patent/DK3837263T3/da active
- 2019-08-12 CA CA3104928A patent/CA3104928A1/en active Pending
- 2019-08-12 FI FIEP19755855.4T patent/FI3837263T3/fi active
- 2019-08-12 RU RU2021106145A patent/RU2769507C1/ru active
- 2019-08-12 RS RS20240963A patent/RS65912B1/sr unknown
- 2019-08-12 SI SI201930813T patent/SI3837263T1/sl unknown
- 2019-08-12 BR BR112021002298-8A patent/BR112021002298A2/pt unknown
- 2019-08-12 MA MA53219A patent/MA53219B1/fr unknown
- 2019-08-12 KR KR1020217004221A patent/KR102879259B1/ko active Active
- 2019-08-12 IL IL279173A patent/IL279173B2/en unknown
- 2019-08-12 ES ES19755855T patent/ES2986417T3/es active Active
- 2019-08-12 MX MX2021001433A patent/MX2021001433A/es unknown
- 2019-08-12 EP EP24183419.1A patent/EP4474017A3/en active Pending
- 2019-08-12 SG SG11202013064WA patent/SG11202013064WA/en unknown
- 2019-08-12 EP EP19755855.4A patent/EP3837263B1/en active Active
- 2019-08-12 AU AU2019322538A patent/AU2019322538B2/en active Active
- 2019-08-12 WO PCT/EP2019/071520 patent/WO2020035424A1/en not_active Ceased
- 2019-08-12 LT LTEPPCT/EP2019/071520T patent/LT3837263T/lt unknown
- 2019-08-12 PL PL19755855.4T patent/PL3837263T3/pl unknown
- 2019-08-12 HR HRP20241201TT patent/HRP20241201T1/hr unknown
- 2019-08-12 CN CN201980053749.3A patent/CN112867720A/zh active Pending
- 2019-08-12 UA UAA202101016A patent/UA127629C2/uk unknown
- 2019-08-12 MY MYPI2021000157A patent/MY210507A/en unknown
- 2019-08-12 CR CR20210077A patent/CR20210077A/es unknown
- 2019-08-12 PT PT197558554T patent/PT3837263T/pt unknown
- 2019-08-13 AR ARP190102303A patent/AR116666A1/es unknown
- 2019-08-13 TW TW108128734A patent/TWI812770B/zh active
-
2020
- 2020-04-09 US US16/844,262 patent/US20200308190A1/en not_active Abandoned
-
2021
- 2021-02-10 CL CL2021000362A patent/CL2021000362A1/es unknown
- 2021-02-11 PH PH12021500013A patent/PH12021500013A1/en unknown
- 2021-02-24 CO CONC2021/0002382A patent/CO2021002382A2/es unknown
-
2022
- 2022-05-20 US US17/749,496 patent/US11802133B2/en active Active
-
2023
- 2023-09-26 US US18/475,065 patent/US12281124B2/en active Active
-
2024
- 2024-09-06 JP JP2024153990A patent/JP2024174966A/ja active Pending
-
2025
- 2025-02-28 US US19/066,414 patent/US20260022130A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CR20210077A (es) | Nuevos compuestos heterocíclicos como inhibidores de la monoacilglicerol lipasa | |
| PH12021500015A1 (en) | New heterocyclic compounds as monoacylglycerol lipase inhibitors | |
| PH12021551167A1 (en) | New heterocyclic compounds | |
| CR20200416A (es) | Nuevos compuestos heterocíclicos | |
| PH12022550472A1 (en) | New heterocyclic monoacylglycerol lipase (magl) inhibitors | |
| PH12022550339A1 (en) | 4,4a,5,7,8,8a-hexapyrido[4,3-b][1,4]oxazin-3-one compounds as magl inhibitors | |
| WO2020243415A3 (en) | Tead inhibitors and uses thereof | |
| MX2021014441A (es) | Inhibidores del dominio asociado mejorador de la transcripcion (tead) y usos de los mismos. | |
| PH12021553018A1 (en) | New egfr inhibitors | |
| PH12022550471A1 (en) | Heterocyclic compounds | |
| ZA202005326B (en) | Heteroaryl compounds as type ii irak inhibitors and uses hereof | |
| PH12017502090A1 (en) | Heterocyclic amides as kinase inhibitors | |
| PH12022550433A1 (en) | Heterocyclic compounds | |
| PH12022550321A1 (en) | 4,4a,5,7,8,8a-hexapyrido[4,3-b][1,4]oxazin-3-one compounds as magl inhibitors | |
| MX2018001890A (es) | Compuestos biciclicos como inhibidores de autotaxina (atx). | |
| PH12021553249A1 (en) | New heterocyclic compounds | |
| MX2025015277A (es) | Inhibidores de masp-2 y metodos de uso | |
| PH12019500664A1 (en) | New isoxazolyl ether derivatives as gaba a alpha5 pam | |
| MX2024008964A (es) | Analogos de rapamicina y usos de los mismos. | |
| EP4706394A3 (en) | Use of alkoxypyrazoles as nitrification inhibitors | |
| MX2022006776A (es) | Composiciones farmaceuticas oftalmicas. | |
| PH12020500674A1 (en) | New isoxazolyl ether derivatives as gaba a alpha5 pam | |
| PH12021550320A1 (en) | Bicyclic heteroaryl derivatives | |
| WO2021249904A3 (en) | Amino-pyrimidine cyclo-amides | |
| PH12018500407A1 (en) | New bicyclic compounds as dual atx/ca inhibitors |